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ABSTRACT 
The binding of hexokinase Types I and II to mitochondria is a putative checkpoint in 
apoptosis.  Evidence supports the specific binding of residues 1 through 15 of hexokinase 
Type I (HKI) to the voltage-dependent anion channel (VDAC) in the outer mitochondrial 
membrane.  Ala4 and Ala8 of HKI play critical roles in mitochondrial binding.  Substitution 
of these residues individually with leucine causes the loss of binding properties.  Identified 
here is the significant role of the methionine at position 1 in the binding of HKI to 
mitochondria.  The following conclusions can be drawn from the properties of mutant HKI 
constructs: Recombinant wild-type HKI is blocked at the N-terminus.  The replacement of 
Ile2 with threonine results in a recombinant HKI with an unblocked amino terminus that does 
not bind to mitochondria.  The extension of HKI at the N-terminus by duplicating its first 
four residues (putting amino acids at positions 0, –1, –2, and –3) retains mitochondrial 
binding properties.  The mutation of Ile at position –2 to threonine results in an unblocked 
amino terminus that still binds to mitochondria.  The mutation of Met1 to leucine in the 
extended construct greatly reduces mitochondrial binding.  The conclusion: blocking of the 
N-terminal methionine is not a significant factor in mitochondrial binding of HKI.  Instead, it 
is the specific structure of the methionine side chain that enables a strong binding interaction.  
Side chains at positions 1, 4, and 8 define a contiguous face on the N-terminal α-helix of HKI 
critical mitochondrial binding.  
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CHAPTER 1: GENERAL INTRODUCTION 
Hexokinase in Metabolism 
The first step in the metabolism of glucose (Glc) is usually phosphorylation catalyzed by 
hexokinase (ATP: D-hexose 6-phosphate transferase, EC 2.7.1.1) to produce glucose-6-
phosphate (Glc-6-P).  Selective expression of isozymic forms of hexokinase, differing in 
catalytic and regulatory properties as well as subcellular localization, is likely to be an 
important factor in determining the pattern of Glc metabolism in mammalian tissues/cells (1).  
Mammals have four types of isozymes for hexokinase: I, II, III, IV.  Hexokinase I (HKI), 
which is also known as brain hexokinase regulates the glucose metabolism in brain tissues, 
kidney and red blood cells (2).  Hexokinase I, II and III have the molecular weights of 
approximately 100 kDa (3), which has both C- and N- terminal halves with significant levels 
of sequence identity to each other and also to the yeast hexokinase (4).  Similarities between 
mammalian isozymes evidently originate from the duplication and fusion of a primordial 
hexokinase gene similar to that of yeast hexokinase (5).  According to Katzen and Schimke, 
the properties of the different types of hexokinase do not vary much from tissue to tissue, but 
are present in different amounts depending on age, stability and nutritional factors (3).  There 
are number of ligands that inhibit brain hexokinase, but Glc-6-P, which is also the product of 
glucose phosphorylation, is probably the main physiological inhibitor (6).  Glc-6-P inhibits 
brain hexokinase by binding to either the C- or N-terminal halves with high affinity (7, 8).  
Under normal physiological conditions, however, inorganic orthophosphate (Pi) seems to 
alleviate the inhibition caused by the Glc-6-P in brain hexokinase (9).  Pi binds to the N-
terminal half of the HKI and lessens Glc-6-P inhibition by an allosteric mechanism that 
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couples both halves of the enzyme (10, 11).  At the higher concentration, Pi inhibits HKI by 
binding to the active site (12). 
 
Fig. 1.  Phosphorylation catalyzed by hexokinase, is the first step in common pathways of 
glucose metabolism (Ref: Wilson J.E., Isozymes of mammalian hexokinase: structure, 
subcellular localization and metabolic function) 
Formation of the Glc-6-P by hexokinase targets glucose to alternative metabolic pathways: 
glycolysis, glycogen synthesis and the pentose phosphate pathway (1) (Fig. 1).  These 
metabolic pathways are associated to different extents with various organs of the body and 
with the different isozymes of mammalian hexokinase.  Type I hexokinase binds to 
mitochondria through interaction with porin, the protein that forms channels through which 
metabolites traverse the outer mitochondrial membrane (OMM).  The Type II isozyme also 
binds to the mitochondria.  Hexokinase Type III and Type IV do not bind to the mitochondria 
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due to the absence of hydrophobic N-terminal residues.  Thus these isozymes might be 
associated with metabolic pathways other than glycolysis (1).  Table 1.1 summarizes the 
similarities and differences between the different types of isozymes. 
Table1.1 Summary of comparison of different isozymes of mammalian hexokinase. 
Properties HKI HKII HKIII HKIV 
Size (kDa) 100 100 100 50 
Tissues 
Brain, Kidney, 
Red Blood Cell 
Skeletal Muscle, 
Fat 
Liver, Intestine, 
Kidney 
Liver, 
Pancreas 
KmGlc (mM) 0.03 0.3 0.003 6 
KmATP(mM) 0.5 0.7 1.0 0.6 
Function of N-
terminal half 
Regulatory Catalytic Regulatory - 
Function of C-
terminal half 
Catalytic Catalytic Catalytic - 
Inhibition by 
Glc-6-P 
Yes Yes Yes No 
Pi Relief Yes No No - 
Subcellular 
localization 
Mitochondria Mitochondria Nuclear Periphery - 
 
Structure of Hexokinase 
The structure of recombinant human brain hexokinase (Fig. 2) has been solved by methods of 
X-ray crystallography (13-19).  Brain hexokinase is a functional monomeric enzyme in 
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solution; however it exists as a dimer in the crystal, with Glc/Glc-6-P or Glc/Pi binding in 
both N- and C-halves (15, 16).  In the dimer, HKI subunits align head-to-tail; with two fold 
rotational symmetry such that the N-terminal domain of one subunit interacts with C-terminal 
domain of other subunit (13, 15-18).  The monomeric structure of an engineered monomer of 
hexokinase I adopts a rod-like conformation similar to that for a subunit in other crystalline 
dimers (14, 19). 
Hexokinase in its monomeric form has two structurally similar halves: N-terminal and C-
terminal domains which are separated by a transition helix which extends from residues 448 
to 475 (14-20).  Each half has a large domain (residues 13-74, 210-447 in N-terminal half 
and residues 466-522, 658-895 in the C-terminal half); and small domain (residues 75-209, 
448-465 in N-terminal half and residues 523-657, 896-913 in C-terminal half) (19).  The 
relative position of the two domains in the C-terminal half in HKI defines two 
conformational states for HKI, open and closed.  The N-terminal half however has been 
observed in only a closed conformation.  Moreover, the N-terminal half evidently is more 
stable than the C-terminal half, as the C-terminal half folds before the N-terminal half (20, 
21). 
Although resembling the catalytically-active C-terminal half, the N-terminal half of the HKI 
is inactive.  Nonetheless, the N-terminal half has a binding pocket for the Glc and Glc-6-P 
which is nearly identical to that of the C-terminal half (16).  Crystal structures reveal the high 
affinity binding site for Pi, which overlaps the binding site of the 6-phosphoryl group of the 
Glc-6-P, is at the N-terminal half (15, 16).  The conformation of the N-terminal half in its Pi 
and Glc-6-P complexed structures differs only in the conformation of loop 445-450 at the N-
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terminal end of the transition helix (19).  Aleshin et al. (16, 19) engineered a monomeric 
form of HKI and crystallized it as a Glc/Glc-6-P complex and as a Glc/ADP complex, 
finding two binding sites for Glc-6-P and two binding sites for ADP. 
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Fig 2. Crystal structure of hexokinase complexed with Glc and Pi. The color code is  as 
follows: yellow, small domains; light purple, large domains; dark purple, segments 
participating in intrachain salt links; blue, bound glucose; red, bound phosphate; green, 
bound metal ions (15). 
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Mitochondrial Binding of Hexokinase I 
Hexokinase I and II have the ability to bind to the outer mitochondrial membrane (OMM), a 
property which requires the first 15 residues of its N-terminus (22-25).  Xie and Wilson (25) 
proposed that the hydrophobic tail is helical and Mulichak et al. (17) confirmed a helical 
structure by a crystal structure determination of the native rat-brain enzyme.  Hexokinase I 
association with the OMM allows preferential access to newly formed mitochondrial ATP 
(22), but perhaps more importantly the interaction with the voltage-dependent anion channel 
(VDAC) putatively is arrests mitochondrially-linked apoptosis (26, 27). 
The N-terminal sequence of the rat brain hexokinase was determined to be 
X-NH-Met-Ile-(Ala, Gln)-Ala-Leu-Leu-Ala-Tyr- 
where X is blocking group at the N-terminal methionine.  The chemical identity of the 
blocking group is unknown, but generally assumed an N-acetyl group.  Elimination of the N-
terminal segment by endogenous proteases in crude brain extracts eliminates mitochondrial 
binding (28).  N-acetylation of the methionine is the norm rather than the exception for many 
cellular proteins and hence, finding a blocked N-terminus on the brain hexokinase is not 
unexpected (29, 30). The N-terminal segment of the hexokinase is readily accessible at the 
surface of the hexokinase.  Hence, it is highly susceptible to proteolytic modification (28). 
Kurakawa et al. (31) discovered that the treatment of brain hexokinase with chymotrypsin 
resulted in the loss mitochondrial binding. Polakis and Wilson (28) later found that 
chymotrypsin removed a limited hydrophobic segment at the N-terminus.  Hence, in an intact 
enzyme, this segment must be located at the surface of the hexokinase molecule, permitting 
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interaction with the mitochondria.  Xie and Wilson (32) have reported through their 
crosslinking study that binding of hexokinase is accompanied by the formation of an 
oligomeric structure (tetramer).  Hence hexokinase associated with the mitochondrial 
membrane might be the mixture of monomer and tetramer.  Wicker et al. later showed that 
the binding of the hexokinase to the mitochondria is a cooperative process with a Hill 
coefficient of approximately 3 (45); however, Rose and Warms found to cooperativity in the 
re-association of HKI with rat-brain mitochondria (22). 
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Fig. 3a.  HKI N-terminal half and VDAC interaction by modeling (Yang Gao, unpublished). 
Orange represent the β-barrel structure of VDAC, yellow represents first 15 residues of the 
hydrophobic N-terminal, while green represent the rest of the N-terminal half.   
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Fig 3b. Closer look at the residues of hexokinase interacting with a particular side of the 
VDAC. Residues colored red are Met1, Ala4, and Ala8. 
 
Glucose-6-phosphate Release of Mitochondrially Bound Hexokinase 
Glc-6-P is not only a potent inhibitor of brain hexokinase at physiological concentrations, but 
it can also release the enzyme from the brain mitochondria (22).  HKI-release of Glc-6-P 
from mitochondria may be the first step in an enzyme degradation pathway (22) and/or a 
process linked to apoptosis (33-36).  Fromm and Zewe (37) demonstrated that Glc-6-P is a 
competitive inhibitor of ATP and linear noncompetitive inhibitor of glucose.  Skaff, et al. 
(38) in 2005 showed that Glc-6-P binding to the N-terminal half is responsible for the release 
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of recombinant human brain hexokinase from the mitochondrion. It has been shown that Glc-
6-P induces conformational change in the N-terminal half of the HKI that consequently 
releases the enzyme from the mitochondrial membrane.  The exact understanding of the 
presumed conformational change has been elusive, as crystal structure reveal Glc-6-P and Pi 
bound N-terminal halves have the same conformation but for a span of five residues 
preceding the transition helix.  Mehyar (39) in 2011 found the residues of the N-terminal 
helix critical to binding with the mitochondrial.  Mutations A4L, A8L and Q5P individually 
caused ten-fold decreases in HKI binding to mitochondria relative to the wild-type enzyme 
(39).  Residues A4 and A8, which define a contiguous surface, does not tolerate large 
hydrophobic side chains (39). 
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Hypothesis 
Some studies suggest that hexokinase binding to the mitochondria is determined by the 
hydrophobicity of the N-terminal tail (40, 41). Co-localization of brain hexokinase with the 
VDAC at the OMM suggests more complex and specific interactions than the general 
hydrophobic interactions with the lipid (26).  Chymotrypsin removes the hydrophobic tail on 
the N-terminal domain and thus prevents the binding of hexokinase to the mitochondria (22, 
28, 31) implying the importance of the first 12-residues in the N-terminal domain.  It was 
also discovered that certain residues among those first 12 residues are critical for hexokinase 
binding to the mitochondria (39).  Leucine replacements of Ala4 and Ala8 abolish 
mitochondrial binding, suggesting these residues come in contact with VDAC.  Met1 could 
be a part of the surface defined by Ala4 and Ala8 that is critical to the interaction of the N-
terminal helix of HKI with the membrane-buried surface of VDAC. 
Due to the blocked N-terminus, our lab has been unsuccessful in obtaining the N-terminal 
sequence of recombinant HKI.  Methionine aminopeptidase (MAP) from Escherichia coli 
specifically cleaves methionine at position 1 provided the residue at position 2 has a small 
side chain (42-44).  In fact, approximately 40% of proteins expressed in Escherichia coli 
begin with threonine (42, 43).  The first five residues of the HKI are Met-Ile-Ala-Ala-Gln.  
The presence of isoleucine does not allow MAP to cleave the methionine from position 1, but 
mutating isoleucine to threonine should enable the action of MAP.  The resulting construct 
should begin with threonine, be amenable to N-terminal sequencing, and be unable to bind to 
mitochondria; however, the loss of binding properties can arise from the presence of a 
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charged N-terminus, the loss of methionine from position 1, and/or the change in position 2 
from isoleucine to threonine. 
In order to determine the factors responsible for the loss of mitochondrial binding properties, 
the first four residues of the N-terminal helix are repeated, defining new sequence positions -
3 to 0.  The extended helix was again blocked and resisted N-terminal sequencing, but bound 
to mitochondria.  Mutation of Ile(-2) to threonine resulted in a construct amenable to N-
terminal sequencing, and without the loss of binding properties.  In the extended and blocked 
construct, the mutation of Ile2 to threonine had little effect on mitochondrial binding, 
whereas the mutation of Met1 to leucine greatly diminished mitochondrial binding.  From the 
observations, the side chain of Met1 is a critical factor in interaction of HKI with the 
mitochondrion, and that positions 1, 4 and 8 define a contiguous surface that recognizes 
VDAC. 
Thesis Organization 
This thesis has three chapters.  Chapter 1 is a general introduction of HKI providing 
background information related to structure, properties of metabolite regulation and 
mitochondrial binding, as well as the goal of research, and a brief summary of the outcome of 
experimental work.  Chapter 2 presents the experimental work in detail, and represents a 
manuscript for publication in a peer-reviewed journal.  Chapter 3 provides a conclusion and 
possible directions of future work. 
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CHAPTER 2: ROLE OF THE N-TERMINUS OF RECOMBINANT 
HUMAN BRAIN HEXOKINASE IN MITOCHONDRIAL BINDING  
Manjit Maskey and Richard Honzatko 
Abstract 
The association of hexokinase I and II (hereafter, HKI and HKII, respectively) with the 
mitochondrion arguably stands as a checkpoint in some pathways of apoptosis.  HKI (often 
called brain hexokinase) requires N-terminal residues 1 through 15 for mitochondrial 
binding.  Ala4 and Ala8 of HKI play critical roles in mitochondrial binding, whereas Thr12 
is far less important.  Met1 would define a contiguous surface with Ala4 and Ala8, assuming 
an α-helical structure for these N-terminal residues.  Recombinant human HKI, as is the case 
for the native enzyme from rat, cannot be sequenced due to a blocked amino terminus.  
Mutation of Ile2 to threonine, enables an Escherichia coli expression system to cleave the 
Met1 from the N-terminus.  The resulting enzyme (Ile2Thr HKI) does not bind to the 
mitochondrion.  The addition of four residues to the N-terminus by the duplication of 
residues 1-4, results in a protein with a blocked N-terminus and wild-type properties of 
mitochondrial binding.  The mutation of Ile(position –2) to threonine again causes cleavage 
of methionine (position –3)from the N-terminus, but does not reduce mitochondrial 
association.  The mutation of Ile2 to threonine in the extended construct has no effect, but the 
mutation of Met1 to leucine greatly reduces mitochondrial association.  The results indicate 
an important and perhaps an essential role for the side chain of position 1 (methionine) in 
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mitochondrial association.  Blockage of the amino terminus does not appear to be a critical 
factor in mitochondrial association of HKI. 
Introduction 
Hexokinase I (ATP: D-hexokose 6-phosphotransferase, EC2.7.1.1) catalyzes the initial 
crucial step of glycolysis, phosphorylating glucose (Glc) to produce glucose-6-phosphate 
(Glc-6-P), using [ATP-Mg]
2–
 as the phosphoryl donor (1-3). 
Glucose + [ATP-Mg]
2–
                                          Glc-6-P
2–
 + [ADP-Mg]
1–
 + H
+
 
Four different kinds of hexokinase have been identified in mammalian tissues (4) – types I, 
II, III, and IV.  Except Type IV hexokinase which has molecular weight of 50 kDa, other 
mammalian hexokinases have molecular weights of 100 kDa (5).  Mammalian hexokinase 
types share approximately 70% of sequence identity (5).  Even N- and C-terminal halves of 
isozymes from I to III show extensive sequence similarity of about 50% and structure 
similarity (5).  These sequence similarities between mammalian isoenzymes evidently 
originate from the duplication and fusion of a primordial hexokinase gene similar to that of 
Type IV hexokinase and yeast hexokinase (6).  The properties of a hexokinase type does not 
differ vary from one tissue to another, but the amount each isozyme differs depending on age 
and nutritional factors (7).  Hexokinase I (HKI), also known as brain hexokinase, can be 
inhibited by the number of ligands including Glc-6-P which is also the product of the 
reaction (4).  Glc-6-P inhibits brain hexokinase catalysis by binding to either the C- or N-
terminal halves with high affinity (8, 9).  Inorganic orthophosphate (Pi) under normal 
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physiological conditions can decrease the inhibition caused by the Glc-6-P (10) through an 
allosteric mechanism that couples both halves of the enzyme (11, 12). 
Even though HKI is a dimer in crystals (13, 14), the monomer is the dominant form in 
solution.  HKI has two structurally similar halves (N-terminal and C-terminal halves), 
separated by a transition helix (residues 448 to 475) (14-20).  The N-terminal half of the 
brain hexokinase is catalytically inactive, but contains a binding pocket for Glc and Glc-6-P 
which is nearly identical to that of the C-terminal half (14).  The crystal structure also reveals 
that N-terminal half has a high-affinity binding site for the Pi which overlaps the binding site 
for the 6-phosphoryl group of Glc-6-P (14, 16).  Glc-6-P, however, inhibits brain hexokinase 
by binding to either half of the enzyme (21). 
Hexokinases I and II bind to mitochondria.  The binding property requires the first 15 
residues of the polypeptide.  None of the residues have formal electrostatic charge, and the 
amino terminus is blocked for HKI isolated from rat brain (22-25).  Xie and Wilson (25) 
proposed that the N-terminal segment is in an α-helical conformation, and Mulichak et al. 
(17) revealed that segment as a helix in a crystal structure.  Mitochondrial association may 
give HKI a competitive advantage over other cytosolic transphosphorylases for 
mitochondrially synthesized ATP (18); however, more recent work suggests that the 
mitochondrial-hexokinase complex acts as a checkpoint in apoptosis (42-44).  Targeting of 
HKI to the mitochondrion may be the result of specific interactions between HKI and the 
voltage-dependent anion channel (VDAC) of outer mitochondrial membrane (45, 46). 
N-terminal sequence of brain hexokinase is  
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X-NH-Met-Ile-Ala-Ala-Gln-Leu-Leu-Ala-Tyr-, 
where X is a blocking group (most probably an acetyl group) on the amino terminus of Met 
1.  Modification of this hydrophobic N-terminal segment by the endogenous proteases in 
crude brain extracts results in the loss HKI-mitochondrial binding properties (26).  Mehyar 
(27) has determined critical roles for Ala4 and Ala8.  Mutations here individually to leucine 
cause a 10-fold decrease in HKI binding affinity to mitochondria (27).  Ala4 and Ala8 as part 
of an α-helix form a contiguous surface that does not tolerate large hydrophobic side chains 
(27), and presumably is in contact with the membrane buried surface of VDAC. 
N-terminal sequencing of HKI (native or recombinant) by Edman degradation has always 
been unsuccessful because of blocking groups at the amino terminus.  N-terminus of the 
recombinant human enzyme from Escherichia coli expression systems is blocked 
(presumably by the N-formyl group); however, methionine aminopeptidase (MAP) in E. coli 
removes methionine from position 1 depending on the residue type at position 2 of the 
polypeptide chain (28, 29).  The mutation of Ile2 to threonine should enable MAP 
modification of wild-type HKI.  The resulting enzyme should begin with Thr2, and be 
amendable to sequencing by Edman degradation.  In fact, this hypothesis is confirmed here 
by experiment.  Ile2Thr HKI can be sequenced by Edman degradation, and moreover, does 
not bind to the mitochondrion.  The loss of mitochondrial binding can be due to the presence 
of a free amino terminus, the mutation of Ile2 to threonine, or to the loss of methionine from 
position 1.  Shown here by the properties of various constructs of HKI, the change in Ile2 to 
threonine and the presence of a free amino terminus are not responsible for the loss of the 
mitochondrial binding property.  Instead, the side chain of methionine at position 1 is critical 
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to wild-type binding properties.  Hence, Met1, along with Ala4 and Ala8 define a contiguous 
surface on the N-terminal helix of HKI that is critical to mitochondrial association. 
Experimental Procedures 
Materials— Adenosine triphosphate (ATP), Nicotinamide adenine dinucleotide phosphate 
(NADP), ampicillin, deoxyribonuclease I (DNase I), bovine serum albumin (BSA), 
leupeptin, protease cocktail inhibitor and phenylmethylsulfonyl fluoride (PMSF) was 
purchased from Sigma.  Diethylaminoethyl (DEAE) high performance liquid 
chromatography (HPLC) resin was from Tosohaas.  E. coli strain BL21 (DE3) competent 
cells were from Novagen.  Glc-6-P dehydrogenase was bought from Roche Molecular 
Biochemicals. I sopropyl-1-thio-β-D-galactopyranoside (IPTG) came from Anatrace.  
Sequencing polyvinylidene fluoride (PVDF) membranes were purchased from Applied 
Biosystems. 
Construction of Wild-type Hexokinase and Mutant Plasmids— Human brain hexokinase 
(HKI) has been cloned into pET-11a as reported in a previous study (31).  Hexokinase 
mutants were created through PCR modification with oligonucleotide primers synthesized at 
DNA Sequencing and Synthesis Facility of Iowa State University.  Mutants Ile2Thr, MIA-
HKI, MIAA-HKI, MTAA-HKI, MIAA-Met1Leu, and MIAA-Ile2Thr were created using 
following forward primers (and their reverse complements), respectively: 
5’-GGAGATATACATATGACCGCCGCGCAGCTCCTG-3’; 
5’-GGAGATATACATATGATCGCCATGATCGCCGCGCAGCTCC-3’; 
5’-GGAGATATACATATGATCGCCGCGATGATCGCCGCGCAGCTCC-3’; 
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5’-GGAGATATACATATGACCGCCGCGATGATCGCCGCGCAGCTCCTG-3’; 
5’-GGAGATATACATATGATCGCCGCGCTGATCGCCGCGCAGCTCCTG-
3’; and 
5’-
GGAGATATACATATGATCGCCGCGATGACCGCCGCGCAGCTCCTG-3’ 
All constructs were confirmed through sequencing of the entire gene by the DNA 
Sequencing and Synthesis Facility at Iowa State University. 
Expression and Purification of Wild-type and Mutant Hexokinase— Wild-type or mutant 
pET-211a-HKI plasmids were transformed into E. coli strain BL21 (DE3). Expression and 
purification of HKI constructs here followed protocols in the literature (31).  The 
concentration of the protein was measure by the Bradford method with bovine serum 
albumin as a standard.  Protein purity was determined by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). 
Pig Liver Mitochondria Isolation— Fresh pig livers were obtained from the Meat Laboratory 
of Iowa State University.  Mitochondrial purification is described (32) with modifications as 
discussed in (1).  Both outer mitochondrial membrane (OMM) and inner mitochondrial 
membrane (IMM) integrities were measured as described previously (33, 34).  Mitochondria 
were stored at –80°C in the presence of storage buffer. 
The HKI Activity Assay— Hexokianse I activity was measured using the glucose-6-phosphate 
dehydrogenase (G6PDH)-coupled spectrophotometric assay at pH 8.0.  Assay solutions have 
3 mM MgCl2, 3 mM DTT, 0.3 mM NADP and 10 µg/ml G6PDH in 50 mM Tris-HCl (pH 
8.0) and concentrations of Glc and [ATP-Mg]
2– 
that varied from 1/5 x Km to 5 x Km.  
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NADPH production was monitored at wavelength of 340 nm.  Assays were initiated by the 
addition of enzyme and linear progress curves monitored for 2 minutes.  Slopes of progress 
curves determined initial rates in µmole/min.  The capacity of the coupling enzymes was 
verified by observing two-fold increase in velocity with a doubling of added hexokinase.  
Fits of the Michaelis-Menten model to initial velocity data used the software GraFit (35). 
Hexokinase Mitochondrial Binding— Purified HKI was dialyzed twice against 
mitochondrial-binding buffer (250 mM sucrose, 5 mM Glc, 50 mM NaCl, 5 mM MgCl2 and 
50 mM HEPES, pH 7.4), and then diluted to 2 mg/ml using the same buffer.  Thirty mg wet 
weight of mitochondrion, thawed on ice, was suspended in 1 mL of mitochondrial-binding 
buffer, and then collected by centrifugation at 11000 x g for 5 minutes at 4°C.  Suspension 
and centrifugation steps were repeated twice.  The pellet was suspended in 1 ml of 
mitochondrial-binding buffer with added HKI (2 mg/ml), protease cocktail inhibitor (0.25 
mg/ml) and PMSF (1 mM).  After 30 minutes on ice, the mixture of HKI and mitochondria 
was centrifuged at 11000 x g for 5 minutes.  Unbound HKI remained in the supernatant fluid 
and was separated from the pellet.  Pelleted mitochondria were suspended in mitochondrial-
binding buffer, less the MgCl2, NaCl, and glucose, and centrifuged again.  This was step was 
twice-repeated. 
N-terminal Sequencing— A thin piece of polyvinylidene fluoride (PVDF) was activated 
using 100% methanol.  PVDF membrane was washed a couple of times with dionized-
distilled water and dipped into 2 mg/ml hexokinase overnight at 4°C.  The PVDF was taken 
out of the protein solution and rinsed sparingly with water before submitting to the Protein 
Facility at Iowa State University. 
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Results 
Rationale for HKI mutants— The N-terminal 15 residues forms an α-helix.  As shown 
previously by Mehyar (27), mutations individually of Ala4 and Ala8 to leucine eliminate 
hexokinase binding to the mitochondrion.  Ala4 and Ala8 lie on the same face of the helix, 
and in a recent model that face is in contact with the outer surface of the β-barrel of VDAC 
(27).  Met1 extends the surface defined by Ala4 and Ala8. 
The mutation of Ile2 to threonine should allow E. coli methionine aminopeptidase (MAP) to 
cleave methionine from the N-terminus, putting Thr2 at the lead position of the polypeptide 
chain.  Hence, the N-terminal sequence of Ile2Thr should be Thr-Ala-Ala-Gln-Leu- rather 
than Met-Thr-Ala-Ala-Gln-.  Thr2-HKI should have an unblocked N-terminal residue and be 
amenable to Edman degradation and sequencing. 
As subsequent experiments revealed the loss of mitochondrial binding due to the Ile2Thr 
mutation further constructs were designed to determine the cause of property-loss (free N-
terminus, the mutation of position 2 to threonine and/or the elimination of methionine at 
position 1).  Constructs MIA-HKI, MIAA-HKI, MTAA-HKI, MIAA-Ile2Thr, and MIAA-
Met1Leu, where the leading letters represent the single-letter code of additional amino acids, 
are simply the duplication of the first three residues of wild-type HKI (MIA), first four 
residues of wild-type HKI (MIAA) or the first four residues of Ile2Thr HKI (MTAA).  
Assuming either or both MIA-HKI and MIAA-HKI would have wild-type binding properties, 
MTAA-HKI would introduce a free amino terminus and retain methionine and isoleucine at 
positions 1 and 2, respectively.  MIAA-Ile2Thr would test whether the mutation at position 2 
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influences binding properties.  MIAA-Met1Leu would test whether the mutation a position 1 
influences binding properties. 
Protein Purity and N-terminal Sequencing— Protein is at least 95% as on the basis of sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (data not shown).  As the 
exact status of the N-terminus is an important aspect of work here, each purified construct 
was subjected to Edman degradation reactions.  N-terminal sequencing of the purified wild-
type- HKI, MIA-HKI, MIAA-HKI, MIAA-Met1Leu and MIAA-Lle2Thr provide no 
sequence information even with samples delivery 100 pmoles of protein.  Ile2Thr and 
MTAA-HKI gave intense chromatographic peaks clearly indicating a sequence of Thr-Ala-
Ala-Gln-Leu- and Thr-Ala-Ala-Met-Ile-, respectively. 
Kinetics of Wild-type and Mutant Hexokinases— The kinetic parameters of the different 
mutants are comparable to those of wild-type HKI (Table 1).  As the N-terminal segment can 
be remove entirely without influencing catalysis or metabolite regulatory properties of HKI, 
the lack of any effect on basic kinetic properties is an expected outcome. 
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Table 1.Kinetic parameters for wild-type and mutant HKI constructs 
HKI Construct kcat(sec
-1
) Km
ATP
(mM) Km
Glc
(µM) 
 
wild-type 73.00 0.80 120 
 
Ile2Thr 74.33 0.8436 126.38 
 
MIA-HKI 71.16 0.777 79 
 
MIAA-HKI 65.26 0.884 85.37 
 
MTAA-HKI 70.43 1.09 126.39 
 
MIAA-Ile2Thr 74.00 0.948 76.21 
 
MIAA-Met1Leu 68.42 0.805 90 
 
Table 1.  Footnote. 
Determination of kcat employed concentration of Glc and ATP of 1.6 mM and 9 mM. 
Determination of Km
ATP 
employed a Glc concentration of 1.6 µM and concentrations of ATP 
from 0.3–5 mM.  Determination of Km
Glc
 employed an ATP concentration of 9 mM and 
concentrations of Glc of 10–600 µM. 
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Mitochondrial Integrity— The outer membrane integrity of isolated mitochondrion was 90% 
as shown by the cytochrome c oxidase activity assay (data not shown). Inner membrane 
integrity was confirmed by mitochondrial uptake of cationic carbocyanide dye JC-1 (data not 
shown). 
Mitochondrial Binding of Wild-type and Mutant Hexokinases— The isolated mitochondria 
are devoid of native hexokinase activity. Fig. 1 shows that the binding response curve of 
wild-type hexokinase from my result is comparable to the wild-type hexokinase binding 
experiment performed by Mehyar (27). Fig.1 and Fig. 2 shows that with the increase in the 
hexokinase concentration, its binding to the mitochondria increase in most of the purified 
proteins. 
Scheme I represents the simplest equilibrium model that accounts for the binding of the wild-
type and mutant hexokinase to the mitochondria. 
E + Q ↔ EQ 
K1 = [EQ] / [E][Q] 
Scheme I 
In Scheme I, K1 represents an association constant for the binding of the HKI construct 
(represented by E) to specific mitochondrial binding sites Q. As demonstrated by the 
previous work, non-specific binding to the mitochondrion by HKI does not occur at the 
significant levels.  The ratio of enzyme bound to the total enzyme, Eo, is as follows 
 R([E]) = (K1[E]) / (1+K1[E])      Eq. 1 
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The concentration of the free specific mitochondrial sites Q is itself a function of the 
concentration of the enzyme.  Algebraic manipulation of the equilibrium expression in the 
Scheme I and the relationship for mass conservation of total enzyme Eo and total specific 
sites Qo gives a quadratic relationship in E: 
a[E]
2
 + b[E] + c = 0 
where a=K1, b=K1(Qo-Eo) + 1, and c = –Eo.  The physical root of the quadratic equation gives 
[E]: 
 [E] = –{K1(Qo–Eo)+1}/2K1 + {K1
2
(Eo–Qo)
2
 + 2K1(Eo–Qo)+1}
1/2
/2K1 Eq. 2 
Substitution of Eq. 2 into the Eq. 1provides a relationship for the fraction of enzyme bound to 
the mitochondria as a function of Eo, Qo, and K1.  The fitting relationship is 
V = sR(Eo, Qo, K1)     Eq. 3 
where ‘s’ is a proportionality constant that relates the fraction of bound enzymes R to the 
velocity V in µmoles/min.  Undefined quantities s, Eo, Qo, and K1 cannot be determined by a 
nonlinear least square fit of the data from a single experiment. Thus, values for some of these 
quantities must come from other determinations. Firstly, one assumes that the HKI-VDAC 
complex has an equal number of HKI and VDAC subunits.  The value for Qo (7.1x 10
-8
 M) 
then is an estimate based on 42000 VDAC molecules per mitochondrion (36), 7.2x10
9
 
mitochondria per mg of total mitochondrial protein (37), and 0.013 mg of mitochondria in 
each 100 µl assay. Moreover, s = Qo x (specific activity) x (assay volume), where the specific 
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activity for HKI is 6x10
9
 µmole min
–1
mg
–1
 the assay volume is in liters.  The data are fit to 
Eq. 3 using K1 as the sole adjustable parameter. 
 
Fig. 1.  HKI binding to the pig liver mitochondria. Plot represents the rate from varying 
concentration of wild-type HKI, from Mehyar’s (27) (▲) data and my data (♦), bound to 1.7 
mg, wet weight mitochondria in each fraction in 250 mM sucrose and 50 mM HEPES, pH 
7.4. The solid lines represent fitted curves using Eq. 3 with the parameters mentioned in the 
Result section and Table 2. 
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Table 2.  Parameters for wild-type and mutant HKI binding to the pig liver 
mitochondria. 
HKI construct 
Association 
constant K1 (M
-1
) 
Wild-type 1.8 X 10
4
 
Ile2Thr .21 X 10
4 
MIA-HKI 2.35 X 10
4
 
MIAA-HKI 2.9 X 10
4
 
MTAA-HKI 1.95 X 10
4
 
MIAA-Ile2Thr 0.94 X 10
4
 
MIAA-Met1Leu 0.32 X 10
4
 
Table 2.  Footnote. 
Parameter K1 is defined in the Results section.  HKI bound to 1.7 mg, wet weight 
mitochondria in each fraction in 250 mM sucrose and 50 mM HEPES, pH 7.5 was measured 
by activity. 
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Fig. 2.  HKI binding to pig liver mitochondria.  Plot represent vrlocities from varying 
concentrations of wild-type (♦), MIA-HKI (▲), MIAA-HKI (ж), MTAA-HKI (■), MIAA-
Ile2Thr (-), MIAA-Met1Leu (■), and Ile2Thr (+) bound to 1.7 mg, wet weight mitochondria 
in each fraction in 250 mM sucrose and 50 mM HEPES, pH 7.5. The solid lines represent fits 
using Eq. 3 with the parameters given in the Results section and Table 2.  
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Discussion 
Various mechanisms can be responsible for the disruption of HKI-mitochondrial binding.  
Mutations might cause a global conformational change in HKI, promoting aggregation and 
conformational states not conducive to mitochondrial association.  Parameters from kinetics 
of the mutant constructs employed here are indistinguishable from those of wild-type HKI, 
ruling out global conformational changes.  Similar results were obtained for mutations of 
other residues of the N-terminal segment (27). 
Pittler et al. (38) proposed that an N-acetyl group is present at the N-terminus of native rat 
brain hexokinase.  Wild-type recombinant HKI resists Edman degradation due to the absence 
of a free amino group at the N-terminus.  This has been demonstrated indirectly by the 
Ile2Thr enzyme, which lacks methionine from position 1 and is amenable to N-terminal 
chemical sequencing.  The N-terminal blocking moiety could be the N-formyl group; 
however, repeated attempts to deblock by standard chemical protocols failed.  There are 
reports of recombinant proteins expressed in E. coli with an N-acetyl group at the N-terminus 
(39).  An acetyl group at the N-terminus cannot be removed chemically without extensive 
hydrolysis of the polypeptide chain, rendering the modification irreversible.  N-terminal 
acetylation of the methionine is of great significance to many proteins, especially to the 
cytosolic proteins which need to escape the transmembrane localization during their 
translocation process (47).  The status of the N-terminus could greatly influence the affinity 
of HKI for the mitochondria, and hence constructs were designed and tested for the effect of 
a free terminal amino group on binding properties.  Although Ile2Thr has relatively low 
binding affinity for the mitochondrion, MTAA-HKI has a free amino terminus and yet binds 
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to mitochondria with affinity comparable to that of wild-type enzyme and MIAA-HKI.  
There is no indication that HKI requires a blocked N-terminus in order to bind to the 
mitochondrion. 
The acetyl-linked N-terminal methionine is critical for some protein-protein interactions (40).  
In such cases, N-acetyl methionine can be without formal charge in a hydrophobic 
environment, whereas a positively charged free amino group would be disfavored (40).  
Evidently a blocked N-terminus for HKI is not essential for mitochondrial association, but 
instead could eliminate uncontrolled chemistry.  A membrane-buried amino group would 
necessarily be neutral (unprotonated) and reactive as a nucleophile.  Over time, an unblocked 
N-terminus could react indiscriminately with electrophilic centers in other membrane-
associated proteins.  The resulting cross-linked proteins would contribute to a pool of 
damaged proteins that could interfere with normal regulatory processes. 
Hydrophobic surfaces contribute to the interaction of HKI with the mitochondrion (41), but 
the specific binding of the brain hexokinase to only mitochondria cannot be explained by a 
nonspecific hydrophobic interaction with the lipid bilayer (25).  Indeed, mutations of Ala4 
and Ala8 to leucine eliminate HKI binding to mitochondria, indicating a specific protein-
protein interaction that targets HKI to the outer membrane of the mitochondrion (27).  Coarse 
grain modeling (Yang Gao, and Richard Honzatko, unpublished) indicates that the surface 
defined by Ala4 and Ala8 is spatially contiguous and has a preferred (low energy) placement 
on the surface of the β-barrel of VDAC.  In that coarse-grain model of a VDAC-HKI 
complex, the center of mass of the N-terminal half of HKI is over the pore of VDAC, in 
proximity to residues that are significant to high affinity HKI-mitochondrial binding.  The 
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model indicates that Met1 and to a lesser extent Ile2 could also participate in hexokinase-
mitochondrial interactions. 
 
Fig 3. Closer look at the residues of hexokinase interacting with a particular side of the 
VDAC. Residues colored red are Met1, Ala4, and Ala8 
 
To investigate the role of Ile2 and Met1 in binding interactions, residues (Met-Ile-Ala-Ala) 
were introduced at the N-terminus, duplicating the first four residues of wild-type HKI.  The 
addition of four residues did not alter binding affinity for the mitochondrion relative to wild-
type enzyme.  The mutation of Ile2 to threonine of this elongated construct (MIAA-Ile2Thr) 
has little effect on HKI-mitochondrial binding; however, the mutation of Met1 to leucine 
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(MIAA-Met1Leu) causes a significant reduction to binding affinity.  This result is consistent 
with the current course-grain model in that Met1 extends the contiguous surface defined by 
Ala4 and Ala8 (Fig. 5).  Moreover, as leucine is a conservative replacement for methionine 
that often does not cause a significant change in protein conformation, the observation of a 
significant effect here indicates a highly specific level of recognition of the side chain of 
methionine by the interacting partner. 
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CHAPTER 3: GENERAL CONCLUSIONS 
The hydrophobicity of 15 N-terminal residues does not explain the specificity of HKI 
binding to the outer membrane of the mitochondrion.  Selective mutations among the first 15 
residues in past investigations indicated the significance of Ala4 and Ala8 in the interaction, 
but the significance of Met1, which is adjacent to Ala4 assuming a helical structure, was 
untested.  Experiments here clearly indicate the importance of the side chain of Met1 in the 
HKI-mitochondrion interaction, rather than the presence of a blocked amino terminus.  The 
surface defined by positions 1, 4 and 8 is contiguous and must couple tightly with a target 
protein as even relatively conservative changes abolish interactions with the mitochondrion.  
Mutations here represent the first test of a recent model that putatively represents the atomic-
resolution interaction of the voltage-dependent anion channel (VDAC) with HKI, and 
happily the model has survived.  Additional mutations of HKI in regions other than the N-
terminal segment will represent more stringent tests of the current model for the VDAC-HKI 
complex. 
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